Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + gemcitabine + yangzheng xiaoji
- Development stage
- Unknown
- Lead developer
- Yiling Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of two cytotoxic chemotherapy agents, cisplatin and gemcitabine, and a traditional Chinese medicine (TCM) formulation, Yangzheng Xiaoji (YZXJ). Cisplatin is a platinum-based alkylating-like agent that causes DNA cross-linking, while gemcitabine is a nucleoside analog that inhibits DNA synthesis. Yangzheng Xiaoji is a capsule containing 16 herbs designed to improve quality of life (QoL) and mitigate chemotherapy-related side effects, such as fatigue and gastrointestinal toxicity, in patients with advanced solid tumors. In the YANG-1 clinical trial (NCT02195453), the addition of Yangzheng Xiaoji to platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) significantly improved QoL and reduced symptoms of fatigue and gastrointestinal reactions without compromising the efficacy of the chemotherapy.
- Other names
- YZXJ + GPYangzheng Xiaoji capsule + cisplatin + gemcitabine
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)HSPB1 (Heat shock protein beta-1)DNA
Beyond the preview
Go deeper on cisplatin + gemcitabine + yangzheng xiaoji.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + gemcitabine + yangzheng xiaoji.